【摘要】 目的:探讨溴隐亭联合诱发排卵药物治疗高泌乳素血症性不孕的临床疗效。 方法 :对 2 3例由高泌乳症引起的不孕症患者均经不孕症系统检查 ,排除其它病因或预先治疗器质性疾病。对本病以溴隐亭治疗为主 ,联合应用促排卵药物。结果:2 3例患者均在 3个月内恢复月经 ;总妊娠率达 10 0 % ,3个月内妊娠 14例 (60 .9% ) ,3～ 6个月妊娠 8例 (3 4.8% ) ,6～ 9个月妊娠 1例 (4.3 % ) ;单纯溴隐亭治疗 11例 ,加用促排卵药物 12例。结论 :治疗高泌乳素血症性不孕 ,应完善不孕症系统检查 ,明确病因诊断 ,应用溴隐亭联合诱发排卵治疗可提高疗效、缩短疗程 ,减少溴隐亭用量更多还原

【Abstract】 Objective: To investigate the clinical use of bromocriptine combining with ovulation induction medicine to cure infertility due to hyperprolactinemia(HPRL). Methods: 23 cases of HPRL were clearly diagnosed by infertility test system. Any organic diseases, if any, were cured before our treatment and any infertility due to other causes was not included. 23 cases of HPRL mainly treated with bromocriptine, and also combined with other ovulation induction medicines. Results: All of 23 cases recovered their menstruation in three months. The pregnancy rate reached 100%. 14 cases (60.9%) got pregnancy in three months, 8 cases (34.8%) in 3~6 months and 1 case (4.3%) in 6~9 months. Among them 11 cases purely with bromocriptine, 12 cases combined with ovulation induction medicine. Conclusion: The infertility test system examination, confirming the early diagnosis and combination of ovulation induction medicine are very necessary during the treatment of HPRL; these factors will improve the therapeutic effects, shorten the cure period and reduce the dosage of bromocriptine.更多还原